| Name | Cinepazide maleate |
| Description | Cinepazide maleate (MD-67350), a maleate salt form of cinepazide, is a vasodilator. |
| In vitro | Cinepazide exhibits strong chronotropic and inotropic effects. Intravenous administration of Cinepazide (1 mg/kg - 3 mg/kg) leads to an 8% increase in heart rate while reducing blood pressure by 4%. Cinepazide selectively enhances the functional activity of 5-HT neurons in the brain, although hypoxia inhibits its activity. Doses of Cinepazide (3 mg/kg - 30 mg/kg) administered intravenously transiently increase renal and femoral arterial blood flow, spinal and carotid blood flow, and cardiac output in anesthetized dogs while decreasing total peripheral resistance, exhibiting a concentration-dependent relationship with these effects. At 30 mg/kg, Cinepazide enhances the dilatory neural response of dog spinal blood vessels to intrathecal adenosine and adenylic acid. Cinepazide (1 mg - 10 mg) amplifies blood flow within spinal vessels in a dose-dependent manner, partially inhibited by pretreatment with intravenous aminophylline and unaffected by autonomic antagonists. Cinepazide is well absorbed, with over 60% excreted within 24 hours. Over five days, the excretion of Cinepazide through feces and urine is 58.3% and 36.7% in rats, 68.6% and 33.4% in dogs, and 38.1% and 61.3% in humans, respectively. |
| Storage | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | Ethanol : < 1 mg/mL (insoluble or slightly soluble)
H2O : 98 mg/mL (183.67 mM), Sonication is recommended.
10% DMSO+40% PEG300+5% Tween 80+45% Saline : 3.3 mg/mL (6.18 mM), Sonication is recommended.
DMSO : 99 mg/mL (185.54 mM), Sonication is recommended.
|
| Keywords | vasodilator | stroke | piperazine derivative | MD67350 | MD 67350 | ischemic | Inhibitor | inhibit | Cinepazide Maleate | Cinepazide | cerebrovascular disease | CalciumChannel | Calcium Channel | Ca2+ channels | Ca channels | brain?infarct |
| Inhibitors Related | Quadrol | Tricaine methanesulfonate | Nisoldipine | 2,4,6-Tri-tert-butylphenol | Chlorocresol | L-Ascorbic acid | L-Phenylalanine | L-Ascorbic acid sodium salt | 1-Octanol | 2-Nitrobenzoic acid | Magnesium Chloride Hexahydrate | Magnesium sulfate |
| Related Compound Libraries | Pain-Related Compound Library | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Inhibitor Library | Neuroprotective Compound Library | NO PAINS Compound Library | Anti-Cancer Approved Drug Library | Bioactive Compounds Library Max | Ion Channel Targeted Library | Anti-Cancer Drug Library |
United States
